Kiniksa Pharmaceuticals reported second-quarter 2026 net product revenue of $243.6 million from Arcalyst, up about 55% from $156.8 million a year earlier.
Total revenue for the quarter was also $243.6 million, compared with $156.8 million in the second quarter of 2025. Net income rose to $25.4 million from $17.8 million.
Operating expenses climbed to $216.4 million from $136.6 million. Within that total: Cost of goods sold increased to $23.6 million from $18.6 million. Collaboration expenses rose to $88.1 million from $52.4 million. Research and development spending more than doubled to $40.9 million from $18.8 million. Selling, general and administrative expenses increased to $63.9 million from $46.9 million.
The company said second-quarter operating expenses included $11.6 million in non-cash share-based compensation, up from $8.9 million a year earlier.
At June 30, Kiniksa had $525.9 million in cash, cash equivalents and short-term investments, with no debt.
Arcalyst’s 2026 revenue outlook was raised to $980 million to $995 million, up from prior guidance of $930 million to $945 million. That implies an increase of $50 million at the low end and $50 million at the high end of the range.
On the clinical side, Kiniksa said KPL-387’s phase 2 data showed a median time to treatment response of 4.0 days, a median time to pain response of 4.0 days, and a median time to CRP normalization of 8.0 days in the 300 mg once-monthly subcutaneous dose group. The pivotal phase 3 trial is now enrolling and dosing patients, with up to about 85 participants planned. As a result of these announcements, the company's shares have moved 23.3% on the market, and are now trading at a price of $78.34. For more information, read the company's full 8-K submission here.
